Haemophilia Society UK responds to emicizumab concerns
The Haemophilia Society has published advice to its members on recent reports on social media ‘about deaths relating to a new treatment for haemophilia A, Emicizumab (Hemlibra)’
Without providing details of the reports, the Society states: ‘Worldwide over 2,500 people have been using Emicizumab. Although a number of deaths have been reported, these were not felt to relate to the Emicizumab treatment’. It advises readers to raise any concerns with their haemophilia team.